Trial Profile
Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Orlistat (Primary)
- Indications Obesity
- Focus Adverse reactions
- Acronyms ORLIFAT
- 02 Sep 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Mar 2011 New trial record